The last two classes of antidiabetic agents introduced in therapy, glucagon peptide-1 receptor agonists (GLP1-RA) and sodium-glucose co-transporter 2 (SGLT2) inhibitors, have proven cardio-renal benefits, which changed the latest guideline recommendations of the American Diabetes Association (ADA), with these drugs being the first-line medication in patients with established cardiovascular disease, heart failure and chronic kidney disease [6,7]. The gene discussed is SLC5A2; the disease is heart failure.